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Abstract
Complete or incomplete intestinal obstruction by viscid faecal material in the terminal ileum and proximal colon – distal intestinal
obstruction syndrome (DIOS) – is a common complication in cystic ﬁbrosis. Estimates of prevalence range from 5 to 12 episodes per
1000 patients per year in children, with higher rates reported in adults. DIOS is mainly seen in patients with pancreatic insufﬁciency,
positive history of meconium ileus and previous episodes of DIOS. DIOS is being described with increasing frequency following organ
transplantation. Diagnosis is based on suggestive symptoms with a right lower quadrant mass conﬁrmed on X-ray. The main differential
is chronic constipation. Treatment consists of rehydration combined with stool softening laxatives or gut lavage with balanced electrolyte
solutions. Rapid ﬂuid shifts have been described following osmotic agents. Avoiding dehydration and optimizing pancreatic enzyme dosage
may reduce the chance of further episodes. Prophylactic laxative therapy is widely used, but is not evidence-based.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Distal Intestinal Obstruction Syndrome (DIOS) is a com-
mon complication in Cystic Fibrosis (CF) patients [1,2].
It is characterized by the accumulation of viscid faecal
material within the bowel lumen combined with sticky
mucoid intestinal content adherent to the intestinal wall of the
terminal ileum and caecum. This mass is strongly connected
to the crypts and villi and difﬁcult to remove. In many
cases, this is a permanent condition, sometimes aggravated
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by new material which explains the intermittent course of the
symptoms. It may present acutely with intestinal obstruction
or, more commonly, sub-acutely with intermittent abdominal
pain generally in combination with abdominal distension.
Characteristically, DIOS patients have a right lower quad-
rant mass which may be palpable and is usually seen on
a plain abdominal X-ray. Consequently, DIOS is deﬁned
as a complete or incomplete intestinal obstruction with a
faecal mass in the ileocaecum; presenting symptoms include
abdominal pain, distension and vomiting [2].
An important differential diagnosis of DIOS is constipa-
tion, which is also common in patients with CF. Unlike DIOS,
symptoms are usually of longer standing and faecal material is
distributed throughout the colon on a plain abdominal X-ray.
The incidence of DIOS with complete intestinal obstruc-
tion was recently studied in children and found to be between
5 and 12 episodes per 1000 patients per year throughout
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Europe [2]. Rates for incomplete obstruction – impending
DIOS – are likely to be higher; DIOS is seen more frequently
in adult populations (35.5/1000 patient years) [3].
2. Pathophysiology
The intestinal epithelium shares the same secretory pro-
cesses seen in the airway, where chloride secretion, together
with an inhibition of sodium absorption, is the driving force
for ﬂuid secretion into the lumen [4–7].
In CF, defective cystic ﬁbrosis transmembrane conductance
regulator (CFTR) function leads to reduced chloride and ﬂuid
secretion. Moreover, an up-regulation of the epithelial sodium
channel (ENaC) enhances sodium and ﬂuid absorption from
the luminal mucus [8]. In the lung, these anomalies combine
to cause dehydration of mucus and plugging of the small
airways; in the intestine they predispose to obstruction.
In addition, in the CF intestine there are other factors
that inﬂuence either the viscosity of luminal contents or
gut motility [9], and may predispose to obstruction or
account for the localization of the obstructive process to the
terminal ileum (Table 1). For example, there is good evidence
that gut transit is prolonged in CF: this affects gastric
emptying and both ileal and colonic transit [10]. This may
reﬂect an underlying inﬂammatory process resulting in enteric
neuromuscular dysfunction [11]. Intestinal wall thickening is
also seen [12]. This involves the muscularis mucosa, and may
be a consequence of the dysmotility and/or an effect of viscid
intestinal contents.
There is little evidence that pancreatic exocrine insuf-
ﬁciency is the primary event in causing obstruction since
DIOS is also seen in patients with pancreatic sufﬁciency [13].
Nevertheless, poorly controlled fat absorption may contribute
to DIOS by altering the viscosity of luminal contents and by
activating the ileal brake [14].
Abnormalities in bile acid absorption may explain the
location of the obstructive process. Normally bile acids are
actively reabsorbed in the terminal ileum via a sodium
gradient-driven co-transporter, the ileal bile acid transporter
(IBAT) [15]. Bile acids also induce secretion via a CFTR-
dependent mechanism [16]. Both these aspects of bile acid
function in the intestine, their stimulation of secretion and
their active re-uptake by the terminal ileum, are affected in CF
and offer a possible mechanism for DIOS and an explanation
for the site of involvement in the distal ileum.
Table 1
Events likely to predispose the bowel to obstruction
(a) Secretory
• Defective chloride and water secretion into gut lumen via CFTR
• Enhanced ﬂuid uptake via ENaC
• Loss of bile-salt triggered secretion in terminal ileum
(b) Impaired motility
• Enteric neuromuscular dysfunction
• Muscular hypertrophy
• Fat malabsorption
Table 2
Risk factors for DIOS
• Severe genotype
• Pancreatic insufﬁciency
• Dehydration
• Poorly controlled fat malabsorption
• History of meconium ileus
• History of DIOS
• Post organ transplantation
• CF related diabetes
3. Risk factors
Several factors have been identiﬁed as predisposing to
DIOS (Table 2).
DIOS is mainly seen in patients with genotypes asso-
ciated with severe phenotypes [1,2,17], although it can be
encountered in patients with genotypes associated with mild
phenotypes. Indeed, the majority of patients with DIOS are
pancreatic insufﬁcient, with less than 10% of DIOS patients
being pancreatic sufﬁcient [2,18].
A previous history of meconium ileus is also a strong risk
factor [19,20]. Almost half of the DIOS patients in a large
European study had presented with meconium ileus at birth
[2], as opposed to a frequency of 15% in the general CF
population [17]. As both conditions probably share a similar
pathophysiology, such as slow intestinal transit and impaired
intestinal secretion, this association seems logical.
A previous DIOS episode will enhance the risk of sub-
sequent episodes of DIOS. The chance of having a further
episode was found to be more than 10 times higher in
patients who had experienced a previous DIOS episode [2].
Poorly controlled fat malabsorption is also frequently reported
in patients with DIOS. Unabsorbed fat entering the distal
ileum will both inhibit gastric emptying and prolong intestinal
transit [10,21], and could therefore induce DIOS.
Dehydration precipitated by intercurrent illnesses, such as
respiratory exacerbation and hot weather might induce DIOS
[1,22]. CF-related diabetes mellitus has also been suggested
as a risk factor for DIOS; however there are no convincing
data to corroborate this hypothesis [1,23].
The risk for DIOS appears to be increased after organ
transplantation, particularly lung transplantation, with a re-
ported incidence as high as 10–20% [24,25]. If not managed
aggressively after transplantation, laparotomy may be re-
quired in the early postoperative period, with an associated
poor outcome [26]. Speciﬁc predisposing factors after trans-
plantation include adhesions due to previous surgery, transient
postoperative adynamic ileus, adverse effects from pain relief
drugs, and circulatory underﬁlling in the acute postoperative
phase.
4. Establishing a diagnosis of DIOS
Patients with CF who experience an acute onset of
abdominal pain and vomiting should be initially seen by a
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Table 3
Differential diagnosis when DIOS is suspected
• Constipation (most common)
• Appendicitis
• Appendicular abscess
• Mucocele of the appendix
• Intussusception
• Crohn’s disease
• Adhesions
• Volvulus
• Fibrosing colonopathy
• Malignancy
physician experienced with CF and its complications, rather
than by a general paediatrician or surgeon. When considering
DIOS, it is important to distinguish this diagnosis from other
common causes of abdominal pain in CF (Table 3) [27,28]
and rule out a surgical aetiology.
Both complete and impending DIOS are associated with
a fairly acute onset of symptoms, with periumbilical and/or
right lower quadrant abdominal pain. Vomiting of bilious
material with progressive, colicky abdominal pain and/or ﬂuid
levels in the small intestine on abdominal radiography are
signs of complete intestinal obstruction. Intermittent episodes
of abdominal pain with nausea, or anorexia without vomiting
are more typical of impending/incomplete DIOS. Radiographs
of the abdomen usually reveal faecal loading in the right lower
quadrant: sometimes multiple air-ﬂuid levels in the dilated
small bowel are seen [29]. In the majority of cases, the
history combined with a palpable mass in the right lower
quadrant, and supported by a characteristic plain abdominal
ﬁlm is sufﬁcient to establish the diagnosis. It should be
noted that a palpable mass in the right lower quadrant may
persist for years without ileus symptoms and it is not per
se an indication for intervention unless the plugs cause
severe obstruction. Protracted or uncharacteristic symptoms
or an atypical radiograph should prompt re-evaluation of the
diagnosis, as should failure to respond to treatment. In such
cases sonography [30] or, if needed, an abdominal computed
tomography (CT) should clarify the diagnosis and may assist
in ruling out an appendiceal abscess which may be missed on
ultrasound.
In DIOS, a CT scan of the abdomen will show signiﬁcant
proximal small-bowel dilatation, with inspissated faecal ma-
terial in the distal ileum (soft-tissue mass) [31,32]. Magnetic
Resonance Imaging (MRI) is rarely used to establish a diag-
nosis, but Magnetic Resonance enterography may be applied
more widely in the future, especially when it is necessary to
repeat examinations [33].
5. Differential diagnosis
In DIOS, there is an acute onset of symptoms versus a
gradual onset of symptoms in constipation. In clinical prac-
tice, the differential diagnosis between impending DIOS and
severe constipation may not always be possible, although an
abdominal radiograph may clarify the diagnosis by showing
faecal accumulation throughout the colon in constipation.
However, this might not be an important issue, as the initial
approach to treatment, i.e. laxatives, is similar.
Appendicitis and intussusception both mimic DIOS. Di-
agnosis in the former is sometimes delayed leading to an
increased rate of appendiceal perforation and abscess forma-
tion in CF [34]. Both diagnoses should be ruled out by clin-
ical examination and abdominal ultrasonography [30,35,36].
However, differentiating acute appendicitis from chronically
distended, swollen, mucoid appendix caused by inspissated
mucoid contents with imaging may be difﬁcult [37].
Intussusception is seen in approximately 1% of CF pa-
tients; it is usually ileocolic, and can subside spontaneously.
Transient asymptomatic small-bowel intussusception, chieﬂy
seen in the jejunum, is not uncommon. Possible pathological
lead points for ileocolic intussusception include inspissated
secretions, enlarged lymphoid follicles or a distended ap-
pendix. Intussusception may also occur as a complication of
DIOS. Plain abdominal radiographs are often non-speciﬁc, but
may show evidence of small bowel obstruction. Sonography
is the primary method of diagnosis in this circumstance,
showing a “doughnut sign” on transverse imaging or a
“pseudokidney” on longitudinal imaging. In adults, clinically
signiﬁcant intussusception is rare.
The clinical presentation of ﬁbrosing colonopathy may
be quite similar to DIOS, with abdominal pain, distension,
vomiting and constipation. However, these symptoms do not
respond to usual medical management of DIOS and the
patient may progress to subacute and later acute obstruction.
Symptoms of colitis with diarrhoea sometimes containing
blood and mucus may also be present [38].
An association between Crohn’s disease and CF has been
suggested in the older literature and should be considered in
atypical cases [39,40].
Small bowel, liver and pancreatic malignancies are being
reported with increasing frequency in CF adults and should
be considered in patients with uncharacteristic or recurrent
symptoms [41].
6. Treatment of acute episode
Treatment of DIOS is still largely empirical as there
are few randomized controlled trials to guide therapy, thus
the following reﬂects best practice. Patients with incomplete
DIOS usually respond to oral rehydration combined with stool
softeners (osmotic laxative containing polyethylene glycol
(PEG). There are several available preparations containing
PEG, which have water and electrolyte concentrations that are
iso-osmotic to avoid signiﬁcant ﬂuid shifts on administration
(Klean-Prep®, Golytely®, Movicol®).
PEG can be given at the dose of 2 g/kg/day, maximum
80–100 g/day, or as a ready to use iso-osmotic PEG solution,
at a dose of 20–40 ml/kg/h up to a maximum of 1 L/h over 8
hours. The aim of such treatment is to achieve fecal efﬂuent
consisting of clear ﬂuid and resolution of pain, abdominal
distension and vomiting.
Alternatively, sodium meglumine diatrizoate (Gastrograﬁn)
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can be administered orally or by naso-gastric tube, at a dose
of 50 ml in 200 ml of water or juice for children <6 years
and 100 ml diluted in 400 ml for older patients on day 1, and
half doses on subsequent days should this be required [16].
The use of N-acetyl cysteine administered orally has been
superseded by the above medication. Prokinetics have shown
some efﬁcacy in post operativeileus and pseudo-obstruction,
however, there is no evidence base to support their use in
DIOS [42].
In patients with complete DIOS, a stepwise approach
is usually employed. In cases of moderate obstruction, in
patients who do not vomit, PEG can be used as above.
The efﬁcacy of intestinal lavage with a balanced electrolyte
osmotic solution either orally or via nasogastric tube was
ﬁrstly reported in 1989 by Koletzko et al. [43]. When DIOS
presents with more severe intestinal obstruction characterised
by bilious vomiting, or when washout therapy has failed,
hospitalisation should be recommended and IV rehydration
and nasogastric aspiration commenced. Gastrograﬁn can be
used by enema (100 ml diluted four times with water) [44].
The advantage is that it is radio opaque, so the procedure of
choice is to give it as retrograde lavage with hydrostatic pres-
sure under direct vision until the terminal ileum is reached.
However, gastrograﬁn may cause considerable ﬂuid shift from
the circulation to the bowel and serious complications have
been reported, including, shock, perforation and necrotizing
entero-colitis [44]. This procedure is only safely performed by
an experienced radiologist. The local installation of diatrizoate
in the caecum by colonoscopy has recently been described as
an alternative approach [45].
With early aggressive medical management, surgery is
seldom required. Laparotomy with washout via enterostomy
should be tried before considering resection of the ileocaecum
[46]. It should be emphasized that comorbidity and even
mortality from surgery are not infrequent.
7. Prophylaxis
As a previous episode of DIOS is a risk factor for
recurrence, maintenance laxative therapy can be considered,
with avoidance of dehydration and reassessment of adequate
pancreatic enzyme dosage. These steps seem logical, although
there is no evidence base. Oral PEG, 0.5–1 g/kg/day to a
maximum of 40 g/day for 6–12 months, is probably the
best choice. Lactulose is also widely used, but it may cause
abdominal pain and ﬂatulence, especially in high doses. The
role of increasing dietary ﬁbre in preventing a subsequent
DIOS episode is unclear.
Suggested preventive measures for patients undergoing
organ transplantation include pretransplant bowel preparation,
early postoperative bowel lavage and enteral feeding with
immediate introduction of pancreatic enzymes [24].
8. Conclusions
These good practice guidelines will assist CF caregivers
to diagnose and treat DIOS promptly and efﬁciently. A
multinational study is currently underway (ESPGHAN and
ECFS) to study DIOS prospectively.
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